Alpha Tau Medical's (DRTS) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Alpha Tau Medical (NASDAQ: DRTS) with a target price of $9.00, suggesting a potential upside of 115.57%.
• Weiss Ratings issued a "sell (d-)" rating for Alpha Tau Medical, contributing to a mixed consensus rating of "Hold" with a price objective of $9.00.
• Alpha Tau Medical's stock is currently down 0.6%, trading at $4.18, with a recent trading volume significantly below its average.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 115.57% from the stock's current price.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $9.00.

Alpha Tau Medical Stock Down 0.6%

Shares of Alpha Tau Medical stock traded down $0.03 during midday trading on Wednesday, hitting $4.18. The company's stock had a trading volume of 15,365 shares, compared to its average volume of 63,336. Alpha Tau Medical has a 1-year low of $2.14 and a 1-year high of $4.69. The company has a quick ratio of 5.81, a current ratio of 10.52 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $354.12 million, a P/E ratio of -8.70 and a beta of 1.07. The stock has a 50-day simple moving average of $3.77 and a 200-day simple moving average of $3.22.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, sell-side analysts expect that Alpha Tau Medical will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Alpha Tau Medical stock. Kovitz Investment Group Partners LLC boosted its holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 601.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 226,320 shares of the company's stock after buying an additional 194,055 shares during the period. Kovitz Investment Group Partners LLC owned approximately 0.32% of Alpha Tau Medical worth $568,000 as of its most recent SEC filing. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.